FRAGMIN Drug Patent Profile
✉ Email this page to a colleague
When do Fragmin patents expire, and what generic alternatives are available?
Fragmin is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in FRAGMIN is dalteparin sodium. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dalteparin sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FRAGMIN?
- What are the global sales for FRAGMIN?
- What is Average Wholesale Price for FRAGMIN?
Summary for FRAGMIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 38 |
| Drug Prices: | Drug price information for FRAGMIN |
| What excipients (inactive ingredients) are in FRAGMIN? | FRAGMIN excipients list |
| DailyMed Link: | FRAGMIN at DailyMed |
Recent Clinical Trials for FRAGMIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Western University, Canada | Phase 3 |
| Valeo Pharma Inc | Phase 3 |
| IQVIA Biotech | Phase 3 |
Pharmacology for FRAGMIN
| Drug Class | Anti-coagulant Low Molecular Weight Heparin |
US Patents and Regulatory Information for FRAGMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;INJECTION | 020287-008 | Apr 4, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-012 | Mar 15, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-005 | Apr 4, 2002 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-007 | Apr 4, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-009 | May 1, 2007 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-001 | Dec 22, 1994 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FRAGMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-001 | Dec 22, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-004 | Jan 30, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | FRAGMIN | dalteparin sodium | INJECTABLE;SUBCUTANEOUS | 020287-003 | Mar 18, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FRAGMIN
See the table below for patents covering FRAGMIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | S56500066 | ⤷ Sign Up | |
| Netherlands | 930104 | ⤷ Sign Up | |
| Canada | 1136620 | FRAGMENTS D'HEPARINE AYANT UNE ACTIVITE ANTICOAGULANTE SELECTIVE (HEPARIN FRAGMENTS HAVING SELECTIVE ANTICOAGULATION ACTIVITY) | ⤷ Sign Up |
| Denmark | 380280 | ⤷ Sign Up | |
| Norway | 150801 | ⤷ Sign Up | |
| European Patent Office | 0014184 | HEPARIN FRAGMENTS HAVING A SELECTIVE ANTICOAGULATION ACTIVITY AND PROCESS FOR THEIR PREPARATION | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
